1 |
Bergdahl M, Bergdahl J. Burning mouth syndrome: prevalence and associated factors. J Oral Pathol Med 1999;28:350-354.
|
2 |
Yamazaki Y, Hata H, Kitamori S, Onodera M, Kitagawa Y. An open-label, noncomparative, dose escalation pilot study of the effect of paroxetine in treatment of burning mouth syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009;107:e6-e11.
DOI
|
3 |
Maina G, Vitalucci A, Gandolfo S, Bogetto F. Comparative efficacy of SSRIs and amisulpride in burning mouth syndrome: a single-blind study. J Clin Psychiatry 2002;63:38-43.
DOI
|
4 |
Femiano F, Scully C. Burning mouth syndrome (BMS): double blind controlled study of alpha-lipoic acid (thioctic acid) therapy. J Oral Pathol Med 2002;31:267-269.
DOI
|
5 |
Palacios-Sanchez B, Moreno-Lopez LA, Cerero-Lapiedra R, Llamas-Martinez S, Esparza-Gomez G. Alpha lipoic acid efficacy in burning mouth syndrome: a controlled clinical trial. Med Oral Patol Oral Cir Bucal 2015;20:e435-e440.
|
6 |
Lopez-Jornet P, Camacho-Alonso F, Leon-Espinosa S. Efficacy of alpha lipoic acid in burning mouth syndrome: a randomized, placebo-treatment study. J Oral Rehabil 2009;36:52-57.
DOI
|
7 |
Carbone M, Pentenero M, Carrozzo M, Ippolito A, Gandolfo S. Lack of efficacy of alpha-lipoic acid in burning mouth syndrome: a double-blind, randomized, placebo-controlled study. Eur J Pain 2009;13:492-496.
DOI
|
8 |
Cavalcanti DR, da Silveira FR. Alpha lipoic acid in burning mouth syndrome: a randomized double-blind placebo-controlled trial. J Oral Pathol Med 2009;38:254-261.
DOI
|
9 |
Ito M, Tokura T, Yoshida K, et al. Five patients with burning mouth syndrome in whom an antidepressant (serotonin-noradrenaline reuptake inhibitor) was not effective, but pregabalin markedly relieved pain. Clin Neuropharmacol 2015;38:158-161.
DOI
|
10 |
Siniscalchi A, Gallelli L, Marigliano NM, Orlando P, De Sarro G. Use of topiramate for glossodynia. Pain Med 2007;8:531-534.
DOI
|
11 |
Kim YD, Lee JH, Shim JH. Duloxetine in the treatment of burning mouth syndrome refractory to conventional treatment: a case report. J Int Med Res 2014;42:879-883.
DOI
|
12 |
Stuginski-Barbosa J, Rodrigues GG, Bigal ME, Speciali JG. Burning mouth syndrome responsive to pramipexol. J Headache Pain 2008;9:43-45.
DOI
|
13 |
Gick CL, Mirowski GW, Kennedy JS, Bymaster FP. Treatment of glossodynia with olanzapine. J Am Acad Dermatol 2004;51:463-465.
DOI
|
14 |
Ueda N, Kodama Y, Hori H, et al. Two cases of burning mouth syndrome treated with olanzapine. Psychiatry Clin Neurosci 2008;62:359-361.
DOI
|
15 |
Apter JT, Allen LA. Buspirone: future directions. J Clin Psychopharmacol 1999;19:86-93.
DOI
|
16 |
Wong H, Dockens RC, Pajor L, et al. 6-Hydroxybuspirone is a major active metabolite of buspirone: assessment of pharmacokinetics and 5-hydroxytryptamine1A receptor occupancy in rats. Drug Metab Dispos 2007;35:1387-1392.
DOI
|
17 |
Loane C, Politis M. Buspirone: what is it all about? Brain Res 2012;1461:111-118.
DOI
|
18 |
Bergman J, Roof RA, Furman CA, et al. Modification of cocaine self-administration by buspirone (buspar): potential involvement of D3 and D4 dopamine receptors. Int J Neuropsychopharmacol 2013;16:445-458.
DOI
|
19 |
Gray AM, Spencer PS, Sewell RD. The involvement of the opioidergic system in the antinociceptive mechanism of action of antidepressant compounds. Br J Pharmacol 1998;124:669-674.
DOI
|
20 |
Benbouzid M, Gaveriaux-Ruff C, Yalcin I, et al. Delta-opioid receptors are critical for tricyclic antidepressant treatment of neuropathic allodynia. Biol Psychiatry 2008;63:633-636.
DOI
|
21 |
Hearn L, Derry S, Phillips T, Moore RA, Wiffen PJ. Imipramine for neuropathic pain in adults. Cochrane Database Syst Rev 2014;5:CD010769.
|
22 |
Ni Riordain R, McCreary C. Patient-reported outcome measures in burning mouth syndrome: a review of the literature. Oral Dis 2013;19:230-235.
DOI
|
23 |
Kuten-Shorrer M, Kelley JM, Sonis ST, Treister NS. Placebo effect in burning mouth syndrome: a systematic review. Oral Dis 2014;20:e1-e6.
DOI
|
24 |
Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004;24(Suppl 1):9-160.
DOI
|
25 |
Scala A, Checchi L, Montevecchi M, Marini I, Giamberardino MA. Update on burning mouth syndrome: overview and patient management. Crit Rev Oral Biol Med 2003;14:275-291.
DOI
|
26 |
Clark G, Dionne R. Orofacial pain: a guide to medications and management. Chichester: John Wiley & Sons; 2012. pp. 240-243.
|
27 |
Sardella A, Lodi G, Demarosi F, Bez C, Cassano S, Carrassi A. Burning mouth syndrome: a retrospective study investigating spontaneous remission and response to treatments. Oral Dis 2006;12:152-155.
DOI
|
28 |
Rodriguez-de Rivera-Campillo E, Lopez-Lopez J. Evaluation of the response to treatment and clinical evolution in patients with burning mouth syndrome. Med Oral Patol Oral Cir Bucal 2013;18:e403-e410.
|
29 |
Barker KE, Batstone MD, Savage NW. Comparison of treatment modalities in burning mouth syndrome. Aust Dent J 2009;54:300-305.
DOI
|
30 |
Min BK, Jung JK, Choi JK. Clinical features affecting the efficacy of systemic clonazepam for management of burning mouth syndrome. J Oral Med Pain 2012;37:161-167.
DOI
|
31 |
Gremeau-Richard C, Woda A, Navez ML, et al. Topical clonazepam in stomatodynia: a randomised placebo-controlled study. Pain 2004;108:51-57.
DOI
|
32 |
de Moraes M, do Amaral Bezerra BA, da Rocha Neto PC, de Oliveira Soares AC, Pinto LP, de Lisboa Lopes Costa A. Randomized trials for the treatment of burning mouth syndrome: an evidence-based review of the literature. J Oral Pathol Med 2012;41:281-287.
DOI
|